Biomarker anal- ysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzum- ab plus docetaxel, pertuzumab plus trastu- zumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Res 2017; 19: 16....
1 研究简介 Ⅱ期Neosphere研究之前的初步分析结果已显示曲妥珠单抗(T)联合多西他赛(D)基础上增加帕妥珠单抗(P)行新辅助治疗可显著改善病理学完全缓解(pCR)。5月11日,《柳叶刀·肿瘤学》在线刊发该研究5年随访结果,报告了5年无进展生存(PFS)率、5年无疾病生存(DFS)率和安全性。该试验入组局部晚期、炎性或早期...
Title:Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY) Room: Hall 1 Date/Time:Saturday,December 8,2018 (7:30AM-9:30AM) Session Inf...
2016年5月11日,英国《柳叶刀肿瘤学分册》在线发表了意大利、波兰、韩国、中国台湾、西班牙、巴西、加拿大、俄罗斯、泰国、英国(罗氏、阿斯利康)的多中心非盲Ⅱ期随机研究(NeoSphere)5年分析:帕妥珠单抗和曲妥珠单抗新辅助治疗局部晚期、炎性或早期HER2阳性乳腺癌患者。 该研究发现,虽然随访5年无进展生存和无病生存的置...
(analysed in patients who had surgery). Secondary and exploratory analyses were not powered for formal statistical hypothesis testing, and therefore results are for descriptive purposes only. The study ended on Sept 22, 2014 (last patient, last visit). This study is registered with ClinicalTrials....